Keeping up with Streptococcus pneumoniae in children living with HIV.

No abstract is available for this paper.

• Publication year

  2023

• Venue

  AIDS (London)

• Publication date

  2023-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/qad.0000000000003544PMID 37930313
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 3 study of safety and immunogenicity of V114, a 15-valent PCV, followed by PPSV23, in children living with HIV.

  2023cited by this paper
• Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs

  2023cited by this paper
• Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination

  2022cited by this paper
• Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).

  2021cited by this paper
• Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)

  2021cited by this paper
• A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).

  2021cited by this paper
• Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines.

  2020cited by this paper
• A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

  2020cited by this paper
• Limited indirect effects of an infant pneumococcal vaccination program in an aging population

  2019cited by this paper
• Challenges to achieving and maintaining viral suppression among Canadian children living with perinatal HIV infection in the Early Pediatric Initiation Canada Child Cure Cohort.

  2019cited by this paper
• Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults

  2018cited by this paper
• Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany.

  2018cited by this paper
• Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco

  2017cited by this paper
• Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

  2017cited by this paper
• Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis

  2017cited by this paper
• Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children

  2017cited by this paper
• Evaluation of Immune Response to Measles Component of MMR Vaccine in Children with HIV Infection Receiving Antiretroviral Therapy

  2015cited by this paper
• Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.

  2015cited by this paper
• Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

  2013cited by this paper
• Streptococcus pneumoniae--a review of carriage, infection, serotype replacement and vaccination.

  2012cited by this paper
• Immunogenicity, Safety, and Predictors of Response After a Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine Series in Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy

  2006cited by this paper
• Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

  1996cited by this paper
• A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics.

  1994cited by this paper
• Pneumococcal disease: prospects for a new generation of vaccines.

  1994cited by this paper

• Keeping up with Streptococcus pneumoniae in children living with HIV: Erratum.

  2023cites this paper